Analysts expect Standard Biotools to report Q2 2026 revenue of $20.80 million and an EPS of -$0.01, with the stock currently trading at approximately $0.87 against an average analyst price target of $1.55. Investors are primarily focused on the company's strategic pivot following the June 2026 announcement of its merger with Treeline Biosciences and the subsequent sale of its mass cytometry business.
This transition aims to stabilize the balance sheet, which was bolstered by a $30 million buyout of contingent payments from Illumina in July. Market participants are looking for signs that operational restructuring and the new clinical-stage pipeline can reverse recent revenue declines and achieve the company's 2026 EBITDA breakeven goal.